Compare Amgen, Inc. (AMGN) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Williams-Sonoma, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Williams-Sonoma, Inc. trades at $221.75 (market cap $26.11B). The key difference: Amgen, Inc. is far larger — about 7.5× Williams-Sonoma, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WSM | |
|---|---|---|
Market Cap | $196.12B | $26.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $240.06 |
52-Week Low | $271.18 | $163.62 |
Enterprise Value | $241.41B | $26.95B |
Dividend Yield | 2.77% | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Williams-Sonoma (WSM) trades at $221.75, up 0.9% with a bullish technical signal. The company demonstrates strong profitability with 46.1% gross margins and 54% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.76 quarterly dividend. Analyst consensus is mixed with 29% buy ratings but a $215.50 price target below current levels.
WSM faces headwinds from revenue contraction and competitive pressures in home furnishings, though strong margins and consistent earnings beats provide support. The stock trades at premium valuations (P/E 24.9, P/S 3.4) requiring sustained execution. Near-term direction hinges on Q2 2026 earnings due next, with technical support at $217 and resistance at $223.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
